ESR1 and breast cancer: Although the EndoPredict Test has not been routinely approved by the FDA, some authorities such as ASCO suggested its use to assist in the decision-making regarding adjuvant chemotherapy treatment in patients with early-stage, ER–positive, and HER2-negative breast cancer [131].